000			01746na a2200265 4500
999			_c7871 _d7871
003			PC7871
005			20190731132740.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aGiangaspro Corradi, Elisa _91345 _eInfecciosas
100			_aRuiz Contreras, Jesús _9811 _ePediatría
245	0	0	_aImpact of Introduction of Conjugate Vaccines in the Vaccination Schedule on the Incidence of Pediatric Invasive Pneumococcal Disease Requiring Hospitalization in Madrid 2007 to 2011. _h[artículo]
260			_bThe Pediatric infectious disease journal, _c2013
300			_a32(6):656-61.
500			_aFormato Vancouver: Picazo J, Ruiz-Contreras J, Casado-Flores J, Giangaspro E, García-de-Miguel MJ, Hernández-Sampelayo T et al. Heracles Study Group. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011. Pediatr Infect Dis J. 2013 Jun;32(6):656-61.
501			_aPMID: 23249906
504			_aContiene 34 referencias
520			_aBackground: Differences in invasive pneumococcal disease (IPD) in children are expected after a change from 7-valent pneumococcal conjugate vaccine (PCV7) to 13-valent pneumococcal conjugate vaccine (PCV13). Universal vaccination with PCV7 started in Madrid in November 2006, and it switched to PCV13 in June 2010. Methods: A prospective, laboratory-confirmed (by culture or polymerase chain reaction), clinical surveillance including all pediatric IPD requiring hospitalization in Madrid was performed in all hospitals with a pediatric department and included four 1-year periods from May 2007 to April 2011. Incidence rate (IR) was calculated as number cases per 100,000 inhabitants using children population data. Results: Six hundred fourteen IPDs were identified: 209 parapneumonic pneumococcal empyema, 191 bacteremic pneumonia, 75 primary bacteremia,
710			_9446 _aServicio de Pediatría-Neonatología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/7/pc7871.pdf _ySolicitar documento
942			_n0 _2ddc _cART